Rapid Pruritus Reduction with Ruxolitinib Cream Treatment in Patients with Atopic Dermatitis

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, provide an overview of atopic dermatitis and review the burden of disease.

Dermatology experts review the design of the TRuE-AD1 and TRuE AD2 phase 3 trial.

Thought leaders provide an overview of the basline characteristics of the TRuE-AD1 and TRuE AD2 phase 3 trial.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.

James Q Del Rosso, DO, takes a closer look at the trial data regarding timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis.

Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.

Clinicians James Q. Del Rosso, DO; Raj Chovatiya, MD, PhD; and Lisa Swanson, MD, PhD, review the study, “Rapid Pruritus Reduction With Ruxolitinib Cream in Patients With Atopic Dermatitis."